Download antimicrobial use

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Pharmacokinetics wikipedia, lookup

Theralizumab wikipedia, lookup

Bilastine wikipedia, lookup

Prescription costs wikipedia, lookup

Pharmacogenomics wikipedia, lookup

Bad Pharma wikipedia, lookup

Adherence (medicine) wikipedia, lookup

Psychedelic therapy wikipedia, lookup

Vancomycin wikipedia, lookup

Dydrogesterone wikipedia, lookup

Ciprofloxacin wikipedia, lookup

Transcript
•
•
•
•
Astemizole (contraindicated)
Chloral hydrate
Cisapride (contraindicated)
Fluconazole
• Terfenadine (contraindicated)
• TMP/SMZ
• Tricyclic antidepressants
Concurrent administration of foscarnet with other nephrotoxic drugs increases the risk of development of renal
impairment.
FOSFOMYCIN (Monurol®)
Usual Dose
Adult women: Single 3 g dose mixed in 3 to 4 ounces of water (UWHC cost/day $37.90)
Indications
1. Uncomplicated urinary tract infections in women due to E. coli and E. faecalis
2. Fosfomycin may have utility in UTIs caused by ESBL-producing organisms and VRE.
Comments
Lab is capable of providing susceptibilities for E. coli and Enterococcus faecialis
organisms only.
GANCICLOVIR (Also see valganciclovir)
Usual Dose
Adult: Treatment 5 mg/kg Q12H IV (UWHC cost/day $87.93).
Maintenance 5 mg/kg Q24H IV (UWHC cost/day $43.97)
Pediatrics:** Induction 5 mg/kg Q12H IV.
Maintenance 5 mg/kg Q24H IV.
Indications
1. Cytomegalovirus (CMV) retinitis, pneumonitis or enterocolitis, esophagitis or bloodstream infections.
2. CMV prophylaxis - oral formulation is now valganciclovir
3. Congenital CMV infections
Comments
Dose adjustment required for renal impairment. See renal dosing guideline on uconnect. Dosing in excess of that
recommended by the renal dosing guideline may occasionally be necessary depending on the clinical scenario.
Ganciclovir has a high incidence of complicating neutropenia (30-40%) and thrombocytopenia (20%). Dosage reductions
should be considered if patients develop neutropenia, anemia or thrombocytopenia. Do not administer to patients with
severe neutropenia. Patients have received longer courses of ganciclovir when the neutropenia has been controlled with
colony-stimulating factors. If colony-stimulating factors are given to maintain ANC >1000, the cost is less than foscarnet
therapy. The alkaline pH of ganciclovir causes pain and phlebitis at the injection site. The manufacturer recommends that
ganciclovir be handled similarly to chemotherapeutic drugs during preparation and administration – discard waste in black
medication bins. Ganciclovir has activity against herpes simplex virus and varicella-zoster virus. Concomitant use of
ganciclovir and acyclovir is unnecessary, and increases costs and toxicity.
Drug Interactions
Ganciclovir increases the hematotoxicity of zidovudine.
Ganciclovir increases the bioavailablity of didanosine, thus increasing the toxicity of didanosine.
Ganciclovir increases drug exposure to tenofovir (and vice-versa) due to competition for drug secretion, potentially
increasing toxicity.
Concurrent administration with tacrolimus increases the risk of nephrotoxicity.
GENTAMICIN
Usual Dose
Adult: Systemic infections 5 mg/kg daily or 2.5 mg/kg Q12H or 1.5 mg/kg Q8H IV (UWHC cost/day $2.48-4.31).
Urinary tract infections 1-3 mg/kg daily IV/IM (UWHC cost/day $0.83-2.48).